ReviewCureus2024

Continuation of CDK4/6 Inhibition and Switching of Hormonal Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.

Allan Ramos-Esquivel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.